3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 1/2
2
Status
Recruiting
2
Active not recruiting
2
Sponsor Class
INDUSTRY
4
Study Type
Interventional
4
Sponsor
Cancer Type
Genitourinary
4
Conditions
Prostatic Neoplasms
4
Ovarian Neoplasms
3
Endometrial Neoplasms
2
Small Cell Lung Carcinoma
1
Neoplasms
1
Bulbo-Spinal Atrophy, X-Linked
1
Breast Neoplasms
1
Advanced Breast Cancer
1
Adenocarcinoma of Lung
1
Interventions
Magnetic Resonance Spectroscopy
49
enzalutamide
46
apalutamide
36
Specimen Handling
34
Androgen Antagonists
30
Abiraterone Acetate
29
Radiosurgery
27
Prednisone
26
darolutamide
25
Docetaxel
23
Pluvicto
22
abiraterone
20
Radiotherapy
19
Biopsy
17
Leuprolide
15
relugolix
11
gallium 68 PSMA-11
11
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
11
Surveys and Questionnaires
11
Radiation
11
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
11
Standard of Care
10
Nivolumab
10
cabazitaxel
9
X-Rays
9
Triptorelin Pamoate
9
bicalutamide
8
Carboplatin
8
pembrolizumab
7
olaparib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
AZD5305
×
90 days
×
Clear all
NCT05367440
2026-06-01
PETRANHA
AstraZeneca
Phase 1/2
Active not recruiting
174 enrolled
NCT06120491
2026-05-27
EvoPAR-PR01
AstraZeneca
Phase 3
Active not recruiting
1,889 enrolled
NCT06952803
2026-05-19
EvoPAR-PR02
AstraZeneca
Phase 3
Recruiting
700 enrolled
NCT07336446
2026-05-01
ANDROMEDA
AstraZeneca
Phase 1/2
Recruiting
300 enrolled